
Opinion|Videos|December 19, 2023
Lower-Risk MDS: Current Treatment Landscape and Unmet Needs
Author(s)Guillermo Garcia-Manero, MD
Dr Garica-Manero provides a brief overview of the current treatment paradigm for lower-risk MDS as well as discussing some unmet needs.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















